Inositol phosphates promote HIV-1 assembly and maturation to facilitate viral spread in human CD4+ T cells.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
01 2021
Historique:
received: 30 09 2020
accepted: 26 11 2020
revised: 02 02 2021
pubmed: 22 1 2021
medline: 27 4 2021
entrez: 21 1 2021
Statut: epublish

Résumé

Gag polymerization with viral RNA at the plasma membrane initiates HIV-1 assembly. Assembly processes are inefficient in vitro but are stimulated by inositol (1,3,4,5,6) pentakisphosphate (IP5) and inositol hexakisphosphate (IP6) metabolites. Previous studies have shown that depletion of these inositol phosphate species from HEK293T cells reduced HIV-1 particle production but did not alter the infectivity of the resulting progeny virions. Moreover, HIV-1 substitutions bearing Gag/CA mutations ablating IP6 binding are noninfectious with destabilized viral cores. In this study, we analyzed the effects of cellular depletion of IP5 and IP6 on HIV-1 replication in T cells in which we disrupted the genes encoding the kinases required for IP6 generation, IP5 2-kinase (IPPK) and Inositol Polyphosphate Multikinase (IPMK). Knockout (KO) of IPPK from CEM and MT-4 cells depleted cellular IP6 in both T cell lines, and IPMK disruption reduced the levels of both IP5 and IP6. In the KO lines, HIV-1 spread was delayed relative to parental wild-type (WT) cells and was rescued by complementation. Virus release was decreased in all IPPK or IPMK KO lines relative to WT cells. Infected IPMK KO cells exhibited elevated levels of intracellular Gag protein, indicative of impaired particle assembly. IPMK KO compromised virus production to a greater extent than IPPK KO suggesting that IP5 promotes HIV-1 particle assembly in IPPK KO cells. HIV-1 particles released from infected IPPK or IPMK KO cells were less infectious than those from WT cells. These viruses exhibited partially cleaved Gag proteins, decreased virion-associated p24, and higher frequencies of aberrant particles, indicative of a maturation defect. Our data demonstrate that IP6 enhances the quantity and quality of virions produced from T cells, thereby preventing defects in HIV-1 replication.

Identifiants

pubmed: 33476323
doi: 10.1371/journal.ppat.1009190
pii: PPATHOGENS-D-20-02164
pmc: PMC7853515
doi:

Substances chimiques

Gene Products, gag 0
Inositol Phosphates 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009190

Subventions

Organisme : NIAID NIH HHS
ID : P50 AI150481
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI150384
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI076121
Pays : United States

Commentaires et corrections

Type : ErratumIn

Déclaration de conflit d'intérêts

No authors have competing interests.

Références

Mol Cell. 2018 Jun 7;70(5):936-948.e7
pubmed: 29883610
PLoS Pathog. 2010 Nov 24;6(11):e1001215
pubmed: 21151640
Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8454-9
pubmed: 15939867
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9401-E9410
pubmed: 30217893
J Virol. 2009 Sep;83(17):8536-43
pubmed: 19515760
Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006924
pubmed: 22762019
J Virol. 2002 Jun;76(11):5667-77
pubmed: 11991995
Nat Commun. 2016 Apr 25;7:11262
pubmed: 27109927
Trends Microbiol. 2013 Mar;21(3):136-44
pubmed: 23266279
EMBO J. 1998 Mar 16;17(6):1555-68
pubmed: 9501077
Science. 2020 Oct 9;370(6513):
pubmed: 33033190
Nature. 2018 Aug;560(7719):509-512
pubmed: 30069050
PLoS Pathog. 2020 Jan 27;16(1):e1008277
pubmed: 31986188
J Biol Chem. 2009 Oct 23;284(43):29692-703
pubmed: 19666477
J Biol Chem. 2005 Jan 21;280(3):1911-20
pubmed: 15531582
J Virol. 2020 Feb 14;94(5):
pubmed: 31801870
Physiol Rev. 2016 Oct;96(4):1261-96
pubmed: 27512009
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E1054-63
pubmed: 26858452
PLoS Pathog. 2020 Aug 10;16(8):e1008646
pubmed: 32776974
J Biol Chem. 2012 Nov 30;287(49):40867-74
pubmed: 23043111
Retrovirology. 2007 Aug 03;4:54
pubmed: 17683545
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10875-9
pubmed: 11526217
J Vis Exp. 2011 Sep 03;(55):e3027
pubmed: 21912370
Bio Protoc. 2018 Aug 5;8(15):
pubmed: 30148188
J Virol. 1992 Oct;66(10):6093-8
pubmed: 1326659
Methods Mol Biol. 2009;485:41-53
pubmed: 19020817
Cold Spring Harb Protoc. 2018 Sep 4;2018(9):
pubmed: 30181224
Cell Rep. 2019 Dec 17;29(12):3983-3996.e4
pubmed: 31851928
Open Biol. 2015 Mar;5(3):150014
pubmed: 25808508
mBio. 2018 Oct 16;9(5):
pubmed: 30327442
PLoS One. 2009;4(5):e5580
pubmed: 19440344
J Virol. 2006 Aug;80(16):7939-51
pubmed: 16873251
Mol Cells. 2017 May 31;40(5):315-321
pubmed: 28554203
Genes Dev. 2007 Jul 15;21(14):1767-78
pubmed: 17639082
Retrovirology. 2013 Mar 06;10:29
pubmed: 23497318
J Virol. 2019 Oct 15;93(21):
pubmed: 31413124
Semin Cancer Biol. 2009 Aug;19(4):218-28
pubmed: 19505649
Virology. 2010 Apr 25;400(1):137-44
pubmed: 20172577
J Virol. 2002 Nov;76(22):11729-37
pubmed: 12388733
J Virol. 2004 Jan;78(2):922-9
pubmed: 14694123
J Virol. 2003 May;77(9):5439-50
pubmed: 12692245
J Biol Chem. 2008 Nov 14;283(46):32024-33
pubmed: 18772135
PLoS Pathog. 2013;9(6):e1003461
pubmed: 23818857
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
J Virol. 2004 Mar;78(5):2545-52
pubmed: 14963157
Virus Res. 2014 Nov 26;193:89-107
pubmed: 25066606
J Virol. 2000 Sep;74(18):8358-67
pubmed: 10954535
Elife. 2018 May 31;7:
pubmed: 29848441
J Virol. 1994 Aug;68(8):5311-20
pubmed: 8035531

Auteurs

Gregory A Sowd (GA)

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, United States of America.

Christopher Aiken (C)

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH